No
Yes
View More
View Less
Working...
Close
OK
Cancel
Confirm
System Message
Delete
Schedule
An unknown error has occurred and your request could not be completed. Please contact support.
Scheduled
Wait Listed
Personal Calendar
Speaking
Conference Event
Meeting
Interest
Schedule TBD
Conflict Found
This session is already scheduled at another time. Would you like to...
Loading...
Please enter a maximum of {0} characters.
Please enter a maximum of {0} words.
must be 50 characters or less.
must be 40 characters or less.
Session Summary
We were unable to load the map image.
This has not yet been assigned to a map.
Search Catalog
Reply
Replies ()
Search
New Post
Microblog
Microblog Thread
Post Reply
Post
Your session timed out.
This web page is not optimized for viewing on a mobile device. Visit this site in a desktop browser to access the full set of features.
2017 GTC San Jose

S7513 - Applications of Generative Adversarial Networks to Drug Discovery in Oncology and Infectious Diseases

Session Speakers
Session Description

Recent advances in deep learning and specifically in generative adversarial networks have demonstrated surprising results in generating new images and videos upon request, even using natural language as input. We'll present the first application of generative adversarial autoencoders (AAE) for generating novel molecules with a defined set of parameters. In the first proof of concept experiment, we developed a seven-layer AAE architecture with the latent middle layer serving as a discriminator. As an input and output, the AAE uses a vector of binary fingerprints and concentration of the molecule. In the latent layer, we also introduced a neuron responsible for growth inhibition percentage, which, when negative, indicates the reduction in the number of tumor cells after the treatment. To train the AAE, we used the NCI-60 cell line assay data for 6252 compounds profiled on MCF-7 cell line. The output of the AAE was used to screen 72 million compounds in PubChem and select candidate molecules with potential anti-cancer properties. This approach is a proof of concept of an artificially intelligent drug discovery engine, where AAEs are used to generate new molecular fingerprints with the desired molecular properties. We'll also present the applications of this approach to discovering new anti-infective drugs and present the roadmap for generating drugs for rare diseases and even for individual patients.


Additional Session Information
All
Talk
AI in Healthcare Summit Computational Biology Deep Learning and AI Healthcare and Life Sciences
Healthcare & Life Sciences Higher Education / Research
50 minutes
Session Schedule